• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by BeyondSpring Inc.

    2/14/22 11:55:39 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BYSI alert in real time by email
    SC 13G 1 tm226449d3_sc13g.htm SC 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No. ________)*

     

    BeyondSpring Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 Par Value

    (Title of Class of Securities)

     

    G10830100

    (CUSIP Number)

     

    Laura Tse

    3000 Sand Hill Road, Building 2, Suite 110

    Menlo Park, CA 94025, USA

    650-233-0688

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

     

    December 31, 2021

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    þ Rule 13d-1(b)
    ¨  Rule 13d-1(c)
    ¨  Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

      

    CUSIP No. G10830100   13G   Page 2 of 5 Pages

     

    1.   NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Decheng Capital Management III (Cayman), LLC
       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨
       
    3.   SEC USE ONLY
     
       
    4.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

       

     

             
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   5.   SOLE VOTING POWER
     
    4,958,142
      6.   SHARED VOTING POWER
     
    4,958,142
      7.   SOLE DISPOSITIVE POWER
     
    4,958,142
      8.   SHARED DISPOSITIVE POWER
     
    4,958,142

     

             
    9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,958,142
       
    10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨
       
    11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    12.67%
       
    12.   TYPE OF REPORTING PERSON (see instructions)

    IA
       
             

     

     

      

    CUSIP No. G10830100   13G   Page 3 of 5 Pages
             

    Item 1.

         
      (a) Name of Issuer
    BeyondSpring Inc.
         
      (b) Address of Issuer’s Principal Executive Offices
    28 Liberty Street, 39th Floor, New York, NY 10005, USA
         

    Item 2.

         
      (a) Name of Person Filing
    Laura Tse
         
      (b) Address of the Principal Office or, if none, residence
    3000 Sand Hill Road, Building 2, Suite 110, Menlo Park, CA 94025, USA
         
      (c) Citizenship
    U.S.
         
      (d) Title of Class of Securities
    Common Stock, $0.0001 Par Value
         
      (e) CUSIP Number
    G10830100
         

    Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) þ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(J).
           

     

     

     

     

     

     

    CUSIP No. G10830100   13G   Page 4 of 5 Pages
             

    Item 4.  Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

             
      (a)   Amount beneficially owned:  4,958,142
             
      (b)   Percent of class:  12.67%
             
      (c)   Number of shares as to which the person has:  
             
          (i) Sole power to vote or to direct the vote 4,958,142
             
          (ii) Shared power to vote or to direct the vote 4,958,142
             
          (iii) Sole power to dispose or to direct the disposition of 4,958,142
             
          (iv) Shared power to dispose or to direct the disposition of 4,958,142
             

    Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

     

    Item 5.  Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.

     

    Instruction. Dissolution of a group requires a response to this item.

     

    Item 6.  Ownership of More than Five Percent on Behalf of Another Person.

     

     None/Not Applicable

     

    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

     None/Not Applicable

     

    Item 8.  Identification and Classification of Members of the Group.

     

     None/Not Applicable

     

    Item 9.  Notice of Dissolution of Group.

     

     None/Not Applicable

     

     

     

     

     

    CUSIP No. G10830100   13G   Page 5 of 5 Pages
             

    Item 10.  Certification.

             
      (a)   The following certification shall be included if the statement is filed pursuant to §240.13d-1(b):
             
          By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.  
             
      (b)   The following certification shall be included if the statement is filed pursuant to §240.13d-1(c):
             
          By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.  
                     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    2/14/2022

    Date

     

       
     

    /s/ Laura Tse

    Signature

     

       
     

    Chief Compliance Officer

    Name/Title 

     

     

     

    Get the next $BYSI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BYSI

    DatePrice TargetRatingAnalyst
    12/2/2021$38.00 → $5.00Buy → Hold
    Jefferies
    12/2/2021$45.00 → $5.00Buy → Underperform
    B of A Securities
    12/1/2021Outperform → Mkt Perform
    William Blair
    12/1/2021Buy → Neutral
    H.C. Wainwright
    9/20/2021$100.00 → $65.00Buy
    HC Wainwright & Co.
    9/9/2021$50.00Outperform
    Robert W. Baird
    9/9/2021$50.00Outperform
    Baird
    8/4/2021$100.00Neutral → Buy
    HC Wainwright & Co.
    More analyst ratings

    $BYSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BeyondSpring downgraded by Jefferies with a new price target

    Jefferies downgraded BeyondSpring from Buy to Hold and set a new price target of $5.00 from $38.00 previously

    12/2/21 5:17:19 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeyondSpring downgraded by B of A Securities with a new price target

    B of A Securities downgraded BeyondSpring from Buy to Underperform and set a new price target of $5.00 from $45.00 previously

    12/2/21 4:49:29 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeyondSpring downgraded by William Blair

    William Blair downgraded BeyondSpring from Outperform to Mkt Perform

    12/1/21 10:55:31 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BYSI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value

    Dr. Lan Huang, PhD, remains Chairman of BeyondSpring, committing her time to SEED Therapeutics, where she serves as Co-Founder, Chairman, and Chief Executive Officer — a structure designed to give each company a fully dedicated executive leaderDr. Jiangwen (Jen) Majeti, PhD, MBA, current BeyondSpring Director, appointed Vice Chairman — deepening Board-level governance and providing strategic continuityMin Qiu appointed Chief Executive Officer with a clear mandate: execute DUBLIN-4, extend Plinabulin's scientific optionality, and build BeyondSpring's global partner and investor baseNa Li appointed Chief Financial Officer to strengthen BeyondSpring's financial position and support capital mark

    6/4/26 7:00:00 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026

    Meaningful clinical benefit: Median PFS at 7.0 months, median DoR is 9.3 months with DCR of 79.5% in metastatic NSCLC patients with acquired resistance to immune checkpoint inhibitorsDurable survival benefit: 12-month OS rate of 78.1% and 24-month OS rate of 58.0% in a patient population with limited treatment optionsGood tolerability and immune activation: Along with increased frequencies of activated CD4+/CD8+ T cells post-treatment, hematology test also showed safety benefit with significantly higher levels of WBCs, neutrophils and platelets. FLORHAM PARK, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a clinical-stage company

    6/2/26 7:00:00 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting

    FLORHAM PARK, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced an upcoming poster presentation of Study 303, an investigator-initiated study supported by Merck, known as MSD outside of the United States and Canada, and BeyondSpring, in patients with 2L/3L NSCLC who progressed on PD-1/PD-L1 inhibitors, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 through June 2 in Chicago, IL. Presentation details are as follows: Title: A Phase 2 Study of Plinabulin (Plin)/Doceta

    5/18/26 7:00:00 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BYSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Huang Lan gifted 260,582 units of Ordinary Shares (SEC Form 4)

    4 - BeyondSpring Inc. (0001677940) (Issuer)

    5/15/26 4:13:11 PM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Kirkby Matthew

    4 - BeyondSpring Inc. (0001677940) (Issuer)

    4/8/26 4:57:26 PM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Fabbio Patrick

    4 - BeyondSpring Inc. (0001677940) (Issuer)

    4/3/26 5:43:32 PM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BYSI
    SEC Filings

    View All

    BeyondSpring Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BeyondSpring Inc. (0001677940) (Filer)

    6/4/26 7:30:18 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by BeyondSpring Inc.

    10-Q - BeyondSpring Inc. (0001677940) (Filer)

    5/13/26 4:30:42 PM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeyondSpring Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BeyondSpring Inc. (0001677940) (Filer)

    5/13/26 7:00:21 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BYSI
    Financials

    Live finance-specific insights

    View All

    BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update

    AACR 2026 Data Positions Plinabulin as a Potential Backbone Agent to Combine with Antibody-Drug Conjugate (ADC)-Based Therapies to Improve Anti-Cancer Efficacy and Tolerability SEED Advances First Molecular Glue Degrader into Clinical Development with Biomarker-Driven Strategy FLORHAM PARK, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced its financial results for the quarter ended March 31, 2026, and provided a corporate update highlighting significant scientific and clinical advancements across its pipeline

    5/13/26 7:00:00 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeyondSpring Reports 2025 Year-End Financial Results

    Plinabulin (BeyondSpring's Lead Program): Phase 3 Survival Benefit Confirmed: Plinabulin combined with docetaxel demonstrated statistically significant overall survival benefit vs. standard of care docetaxel in EGFR wild-type NSCLC patients whose tumors progressed after first line therapy — DUBLIN-3 study results published in The Lancet Respiratory Medicine Confirmatory Trial Planned: Based on DUBLIN-3 Phase 3 data and US FDA discussions, BeyondSpring is advancing DUBLIN-4, a confirmatory global Phase 3 study in a biomarker-selected EGFR wild-type NSCLC patient population progressed on immune checkpoint inhibitors (NCT07361484)Overcoming Immunotherapy Resistance: Early clinical data at MD A

    3/25/26 8:30:00 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones

    Plinabulin Final Phase 3 Data Published in The Lancet Respiratory Medicine, Demonstrating Overall Survival Benefit in 2L/3L NSCLC EGFR Wild Type vs. DocetaxelPlinabulin Phase 2 Data Highlights Potential to Resensitize Tumors Progressed on PD-1/PD-L1 Inhibitors in Metastatic NSCLCSEED Therapeutics Enters into Targeted Protein Degradation Research Collaboration with Eisai with potential payment to SEED of up to $1.5 Billion and Completes $24 Million First Close of Series A-3 FinancingSEED Therapeutics' Lead Oncology Asset RBM39 Degrader Granted Rare Pediatric Disease and Orphan Drug Designations by the FDA FLORHAM PARK, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI

    3/27/25 7:00:00 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BYSI
    Leadership Updates

    Live Leadership Updates

    View All

    BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value

    Dr. Lan Huang, PhD, remains Chairman of BeyondSpring, committing her time to SEED Therapeutics, where she serves as Co-Founder, Chairman, and Chief Executive Officer — a structure designed to give each company a fully dedicated executive leaderDr. Jiangwen (Jen) Majeti, PhD, MBA, current BeyondSpring Director, appointed Vice Chairman — deepening Board-level governance and providing strategic continuityMin Qiu appointed Chief Executive Officer with a clear mandate: execute DUBLIN-4, extend Plinabulin's scientific optionality, and build BeyondSpring's global partner and investor baseNa Li appointed Chief Financial Officer to strengthen BeyondSpring's financial position and support capital mark

    6/4/26 7:00:00 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors

    NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- SEED Therapeutics (SEED), an innovative global biotech company focused on engineering "molecular glues" and harnessing its targeted protein degradation (TPD) platform to attack previously undruggable targets, has appointed eminent international lawyer Ko-Yung Tung to its Board of Directors. SEED is a subsidiary of BeyondSpring (NASDAQ:BYSI), a global clinical-stage biopharmaceutical company developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. Mr. Tung has served as a director and strategic advisor to leading international corporations and advisory councils, including Eisai Co., Ltd., Hawa

    10/23/23 7:45:00 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEED Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors

    Former Director at Eli Lilly, HSBC and MastercardBrings Almost Five Decades of Experience in Finance, Strategy and Risk Governance NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- SEED Therapeutics (the "Company"), a BeyondSpring (NASDAQ:BYSI) subsidiary and global research company focused on harnessing and engineering "molecular glues," a targeted protein degradation (TPD) platform to attack previously believed undruggable targets, today announced that it has appointed Jackson Tai to its Board of Directors. Mr. Tai has most recently retired, or will soon retire, as a Non-Executive Director of Eli Lilly (after 10 years), HSBC (after 7 years), and Mastercard (after 15 years). He brings almost 5

    6/20/23 8:00:00 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BYSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by BeyondSpring Inc.

    SC 13G/A - BeyondSpring Inc. (0001677940) (Subject)

    11/14/24 9:52:50 PM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by BeyondSpring Inc. (Amendment)

    SC 13G/A - BeyondSpring Inc. (0001677940) (Subject)

    2/14/24 4:30:59 PM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by BeyondSpring Inc. (Amendment)

    SC 13G/A - BeyondSpring Inc. (0001677940) (Subject)

    4/7/23 5:02:43 PM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care